Last reviewed · How we verify
NCT06086015
Apply tACS to Alleviate Anxiety Symptoms
Phase 2 trial testing transcranial alternating current stimulation (tACS) in Anxiety Disorders in 40 participants. Status unknown.
30 June 2024
Quick facts
| Lead sponsor | NeuroCognitive and Behavioral Institute Clinical Research Foundation |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 1 June 2021 |
| Primary completion | 30 June 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- transcranial alternating current stimulation (tACS)
Conditions studied
- Anxiety Disorders — all drugs for Anxiety Disorders →
Sponsor
NeuroCognitive and Behavioral Institute Clinical Research Foundation
Who can join
5 and older, any sex, with Anxiety Disorders. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a clinical research trial exploring the efficacy of non-invasive neuromodulation (NM) intervention in the treatment of anxiety. The NM used in this study consists of 25 minutes of 5 hz transcranial alternating current stimulation (tACS) titrated up to 2mA targeting the anterolateral amygdala across 12 treatment sessions with a 3-4 week time period. The studied population includes patients with the following anxiety disorders: generalized anxiety disorder (GAD), social anxiety disorder (SAD), separation anxiety disorder of childhood, and post-traumatic stress disorder (PTSD). Participants will be randomly assigned to tACS or sham, cross-over, then followed by an optional open-label extension phase.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06086015
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of transcranial alternating current stimulation (tACS)
Trials testing the same drug.
- NCT06968689 — Spatiotemporal Thalamocortical Alterations Underlie Experimental and Chronic Pain · NA · recruiting
- NCT06501755 — Effects of Individualized Theta-tACS on a Working Memory Training at SCD · NA · not yet recruiting
- NCT06285721 — Delirium Treatment With Transcranial Electrical Stimulation · NA · recruiting
- NCT06172413 — Transcranial Alternating Current Stimulation for Treatment-Resistant Depression · NA · unknown
- NCT05708001 — Improvement of Memory in Mild Cognitive Impairment · NA · recruiting
Other recruiting trials for Anxiety Disorders
Currently open trials in the same condition.
- NCT07340281 — Biomarkers for Exercise · NA · recruiting
- NCT07432945 — In Vivo Exposure vs. Videochat-Based Vicarious Exposure · NA · recruiting
- NCT07316374 — AI Chatbots for Anxiety Mental Health Literacy · NA · active not recruiting
- NCT07123467 — Cannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder · Phase 3 · recruiting
- NCT07174947 — SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depre · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06086015 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by NeuroCognitive and Behavioral Institute Clinical Research Foundation
- Last refreshed: 18 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06086015.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing